July 19th 2024
A recent case series reviewed the treatment patterns and effects of therapies on 89 pediatric patients with CCD.
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Retinoic acid metabolism inhibitor causes less irritation
October 1st 2001Washington - A series of cutaneous pharmacology studies conductedwith a selective retinoic acid metabolism inhibitor suggest this novel compoundhas the potential for treating a variety of retinoid-responsive dermatologicdiseases but with the advantage of causing less irritation compared to retinoicacid, Gerard J. Gendimenico, Ph.D., said at the Society for InvestigativeDermatology meeting.